Adicet Bio shares are trading lower after the company shared safety and efficacy data from Phase 1 ADI-001 study for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
Portfolio Pulse from Benzinga Newsdesk
Adicet Bio has released safety and efficacy data from its Phase 1 ADI-001 study for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma, which has led to a decrease in its share price.
June 27, 2023 | 5:16 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Adicet Bio's stock price has fallen following the release of data from its Phase 1 ADI-001 study.
The release of safety and efficacy data from a clinical trial can significantly impact a biotech company's stock price. In this case, the data from Adicet Bio's Phase 1 ADI-001 study has led to a decrease in its share price, indicating that the market may have had negative perceptions of the results.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100